An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Kissei

Status and phase: Completed; Phase 3

Conditions: Spinocerebellar Degeneration

Treatments: Drug: KPS-0373, Low dose; Drug: KPS-0373, High dose

Study type: Interventional

Funder types: Industry

Identifiers

NCT01970111

KPS1302

Details and patient eligibility

About

The purpose of this study is to evaluate the long-term safety, efficacy, and pharmacokinetics of KPS-0373 in SCD patients.

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Japanese SCD patients with mild to moderate ataxia (Completion of the KPS1301 study)

Exclusion criteria

• Less than 75% of compliance in KPS1301 study

Trial design

0 participants in 1 patient group

KPS-0373

Experimental group

Treatment:

Drug: KPS-0373, High dose

Drug: KPS-0373, Low dose